Table 3 Main model analysis: incremental costs, QALYsDW gained and ICERs for the CCC intervention compared to business-as-usual
From: Cancer care coordinators in stage III colon cancer: a cost-utility analysis
Incremental costs per patient (NZ$) | QALYsDW) gained per patient | ICER (NZ$ per QALYDW) | |
|---|---|---|---|
Model 1: Averaged over heterogeneity and stochastic variation; input parameter uncertainty only | |||
Mean | $ 2,271 | 0.121 | $ 18,881 |
2.5 % percentile | $ 1,225 | 0.070 | $ 13,442 |
Median | $ 2,226 | 0.119 | $ 18,786 |
97.5 % percentile | $ 3,641 | 0.185 | $ 24,610 |
Model 2: Averaged over stochastic variation; both heterogeneity and input parameter uncertainty included in distribution of outputs | |||
Mean | $ 2,239 | 0.120 | $ 23,393 |
2.5 % percentile | $ 992 | 0.036 | $ 6,290 |
Median | $ 1,972 | 0.113 | $ 17,864 |
97.5 % percentile | $ 5,007 | 0.252 | $ 72,041 |